Advertisement
GMAB Forex Haberleri
Genmab Submits NDA For Epcoritamab In Japan For Relapsed/Refractory Large B-Cell Lymphoma
Genmab A/S (GMAB) announced Wednesday that the company has submitted a Japan new drug application (JNDA) to the Ministry of Health, Labor and Welfare (MHLW) of Japan for subcutaneous epcoritamab (DuoBody-CD3xCD20)
RTTNews
|
1014 gün önce
